Bempedoic Acid (ETC-1002): A Current Review.

Link to article at PubMed

Related Articles

Bempedoic Acid (ETC-1002): A Current Review.

Cardiol Clin. 2018 May;36(2):257-264

Authors: Saeed A, Ballantyne CM

Although statins are first-line therapy for low-density lipoprotein cholesterol (LDL-C) reduction, many individuals on maximally tolerated statin therapy have elevated LDL-C. Bempedoic acid (ETC-1002) is a novel once-daily LDL-C-lowering agent in phase 3 clinical trials. In phase 1 and 2 studies, ETC-1002 was efficacious in lowering LDL-C when used as monotherapy and when added to statin and/or ezetimibe and was well tolerated in patients with statin intolerance. ETC-1002 also improved cardiometabolic risk factors. Ongoing phase 3 studies of ETC-1002 are evaluating its long-term efficacy and safety, and effects on cardiovascular events. This article discusses current evidence and future directions for ETC-1002.

PMID: 29609755 [PubMed - in process]

Leave a Reply

Your email address will not be published.